Thank you ohm, I remember you stating that with leronlimab CD8 increases.....and remember from the videos on the CytoDyn website that leronlimab binds a specific spot on the CCR5 while still allowing functionality whereas other CCR5 antagonists are ‘deep buried’ and block all entry into the receptor.
I know some conversations I had on SA where this was a concern if leronlimab would have success in cancer (like maraviroc showed) due to not blocking the entire receptor? Time will tell, but based on preclinical comparisons things look promising.
(1)
(0)
CytoDyn Inc (CYDY) Stock Research Links
Please do your own due diligence. All my posts and comments are not to be considered investment advice.